Please rate this video!

ASH 2017 | A “chemo-sparing” MRD-driven strategy for CLL

Please rate this video!

Florence Cymbalista

This is an exciting time for chronic lymphocytic leukemia (CLL) research, with the possibility of chemotherapy-free treatment approaches. In this interview, Florence Cymbalista, MD, of Avicenne Hospital, Bobigny, France, discusses the Phase II study of obinutuzumab plus ibrutinib, followed by a “chemo-sparing” strategy, in treatment-naïve CLL patients (ICLL07GAI; NCT02666898). The preliminary results are encouraging, with the full dataset highlight anticipated at next year’s meeting. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter